Change at the Board of Directors
WntResearch today announced that a member of the company’s Board of Directors, Professor Bengt Glimelius, has been appointed to lead the issuing of guidelines for colorectal cancer care in Sweden, by The National Board of Health. Since this assignment is incompatible with board positions at pharmaceutical companies, Professor Glimelius has informed the company that he will have to leave his position at WntResearch. He will however continue as an independent medical consultant to the company.
”We congratulate Bengt Glimelius with the prestigious assignment to lead the health authorities important task to update the national cancer care guidelines, and are looking forward to his continued support to our company as an independent consultant” says Peter Ström, Chairman of the Board of Directors at WntResearch.
Bengt Glimelius will leave his position as board member in August 2016.
For further information, please contact:
Peter Ström, Chairman of the Board, WntResearch
Telephone: +46 73 715 3587
WntResearch has entered the clinical development phase with the company's first drug candidate, Foxy-5, which in animal models has been shown to dramatically inhibit the spreading of tumors (metastasis). The company goal is to commercialize new drugs against tumor metastasis. WntResearch is based on research from Professor Tommy Andersson and his research group at Lund University. Their research is aimed at developing innovations based on the protein Wnt-5a and its role in cancer. In addition to Foxy-5, which is in phase 1 clinical development, the company has a preclinical development program - Box-5. In addition to Foxy-5, which is in phase 1 clinical development, the company has a preclinical development program - Box-5. This is a peptide carrying the potential to inhibit metastases in some cancer forms where Foxy-5 is not an adequate treatment.
WntResearch AB is a public company listed on AktieTorget. For more information see http://www.wntresearch.com